Key Highlights from SNMMI 2024 - Global Oncology Academy

ReachMD Healthcare Image

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Etranacogene Dezaparvovec for Hemophilia B: Efficacy and Safety Four Years Post-Infusion
Etranacogene Dezaparvovec for Hemophilia B: Efficacy and Safety Four Years Post-Infusion
Clinician's Roundtable
Etranacogene Dezaparvovec for Hemophilia B: Efficacy and Safety Four Years Post-Infusion
- Brian P. McDonough, MD, FAAFP
- Guy Young, MD
An Analysis of Subcutaneous Versus Intravenous Atezolizumab in NSCLC
An Analysis of Subcutaneous Versus Intravenous Atezolizumab in NSCLC
Project Oncology®
An Analysis of Subcutaneous Versus Intravenous Atezolizumab in NSCLC
AML Care: Examining the Efficacy and Safety of a Triplet Combination Therapy
AML Care: Examining the Efficacy and Safety of a Triplet Combination Therapy
Project Oncology®
AML Care: Examining the Efficacy and Safety of a Triplet Combination Therapy
- Charles Turck, PharmD, BCPS, BCCCP
- Anthony Stein, MD
Nanrilkefusp Alfa: A Promising Subcutaneous IL-15Rβγ Superagonist
Nanrilkefusp Alfa: A Promising Subcutaneous IL-15Rβγ Superagonist
Project Oncology®
Nanrilkefusp Alfa: A Promising Subcutaneous IL-15Rβγ Superagonist